Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458064 | 0.89 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2CYP11B2 | |
| SCHEMBL19615467 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2CYP11B2 | |
| SCHEMBL25026384 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL18588192 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL26641323 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL25303284 | 0.80 | MEN1 (0.43) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL21458082 | 0.77 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2CYP11B2 | |
| SCHEMBL19615485 | 0.77 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2CYP11B2 | |
| SCHEMBL12384327 | 0.77 | USP2 (0.48) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL12445298 | 0.77 | USP2 (0.48) | USP2SMN1; SMN2NR1H2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-09-06 | — | — | US | disclosed |
| EP-3344630-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | MRPL21, MRM1, MT-CO1 | USP2 4611/4885SMN1; SMN2 1346/4885NR1H2 4254/4885 |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | MRPL21, MRM1, MT-CO1 | USP2 4611/4885SMN1; SMN2 1346/4885NR1H2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.